BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 11, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease

INDICATION: Dyslipidemia

Rat studies suggest GHRH receptor antagonists could help treat dyslipidemia associated with Type I diabetes. A rat model of Type I diabetes had higher GHRH receptor levels in the small...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >